Business
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 – continuing Idorsia’s trajectory towards profitabilityAprocitentan (TRYVIO/JERAYGO) the first and only dual ERA indicated for systemic hypertension and the only new medicine to be included in the ACC/AHA Hypertension Management guidelinesOperating cash runway extended beyond profitability into 2028 following CHF 65.6 millio
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/atcBYtwjtI326vFfueDYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 – continuing Idorsia’s trajectory towards profitability","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"Aprocitentan (TRYVIO/JERAYGO) the first and only dual ERA indicated for systemic hypertension and the only new medicine to be included in the ACC/AHA Hypertension Management guidelines","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating cash runway extended beyond profitability into 2028 following CHF 65.6 million financing with oversubscribed demand from top-tier US and European institutional investors","length":179,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":552,"olType":false},{"type":"text","content":"Allschwil, Switzerland – October 30, 2025Idorsia Ltd (SIX: IDIA), announces 9-month 2025 financial results. Outstanding sales performance of QUVIVIQ coupled with significantly lower operating expenses keeps Idorsia on-track to achieve overall profitability by the end of 2027.","length":277,"tagName":"p"},{"type":"text","content":"Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented: “I focused my first 100+ days on supporting the commercial teams to drive QUVIVIQ’s growth, progressing discussions to bring TRYVIO to market, prioritizing and advancing our pipeline assets in a financially disciplined manner, and securing our financial situation. I’m very happy to report that we progressed on all fronts. Increased QUVIVIQ sales, coupled with the decrease in OPEX, are keeping us on track to profitability. The team has done an outstanding job, successfully delivering a ...